Zavegepant

Zavegepant
Clinical data
Trade names	Zavzpret
Other names	BHV-3500
License data	US DailyMed: Zavegepant;
Routes of; administration	Nasal
Drug class	Calcitonin gene-related peptide receptor antagonist
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide;
CAS Number	1337918-83-8; as HCl: 1414976-20-7;
PubChem CID	53472683; as HCl: 134819878;
DrugBank	DB15688;
ChemSpider	30814207;
UNII	ODU3ZAZ94J; as HCl: 000QCM6HAL;
KEGG	D11898; as HCl: D11899;
ChEBI	CHEBI:229643;
ChEMBL	ChEMBL2397415; as HCl: ChEMBL4650220;
Chemical and physical data
Formula	C36H46N8O3
Molar mass	638.817 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O;
	InChI InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1; Key:JJVAPHYEOZSKJZ-JGCGQSQUSA-N; Key:VQDUWCSSPSOSNA-RYWNGCACSA-N;

Zavegepant, sold under the brand name Zavzpret, is a medication used for the treatment of migraine.^[1] Zavegepant is a calcitonin gene-related peptide receptor antagonist.^[1] It is sprayed into the nose.^[1] It is sold by Pfizer.^[1]

The most common adverse reactions include taste disorders, nausea, nasal discomfort, and vomiting.^[1]

Zavegepant was approved for medical use in the United States in March 2023.^[1]^[2]^[3]^[4]

Medical uses[edit]

Zavegepant is indicated for the acute treatment of migraine with or without aura in adults.^[1]^[5]^[6]

^ ^a ^b ^c ^d ^e ^f ^g ^h "Zavzpret- zavegepant spray". DailyMed. 9 March 2023. Retrieved 25 August 2023.
^ "Drug Approval Package: Zavzpret". U.S. Food and Drug Administration (FDA). 3 April 2023. Retrieved 25 August 2023.
^ "Pfizer's Zavzpret (Zavegepant) Migraine Nasal Spray Receives FDA Approval" (Press release). 10 March 2023.
^ Dhillon S (June 2023). "Zavegepant: First Approval". Drugs. 83 (9): 825–831. doi:10.1007/s40265-023-01885-6. PMC 10209931. PMID 37227596.
^ Khan ZZ, Ahmed U, Shahzad F, Ali M, Tousif K, Ahmed U, et al. (July 2023). "Safety and Efficacy of Zavegepant in Treating Migraine: A Systematic Review". Cureus. 15 (7): e41991. doi:10.7759/cureus.41991. PMC 10428082. PMID 37593294.
^ Martirosov AL, Giuliano C, Shupp M, Channey S, Kale-Pradhan PB (October 2023). "Zavegepant Intranasal Spray for Migraines". The Annals of Pharmacotherapy: 10600280231209439. doi:10.1177/10600280231209439. PMID 37897226. S2CID 264543368.

Clinical trial number NCT04571060 for "Randomized Trial in Adult Subjects With Acute Migraines" at ClinicalTrials.gov
Clinical trial number NCT03872453 for "Acute Treatment Trial in Adult Subjects With Migraines" at ClinicalTrials.gov

This analgesic-related article is a stub. You can help Wikipedia by expanding it.